TVRD
Tvardi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.91
+3.24%Aug 14, 2026, 00:00 UTC
Tvardi Therapeutics reported a net loss of $6.5 million for Q2 2026, compared with net income of $4.2 million in Q2 2025, with research and development expenses of $4.0 million and general and administrative expenses of $2.6 million.